Miromatrix CEO Jeff Ross to Present at the Innovations in Solid Organ and Hematopoietic Stem Cell Transplant Virtual Event – GlobeNewswire

EDEN PRAIRIE, Minn., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced CEO Jeff Ross will present at the Innovations in Solid Organ and Hematopoietic Stem Cell Transplant Virtual Event. The two-day virtual event held this year on September 28-29, will focus the first day on solid organ transplant (SOT), in particular, kidney transplants, and the second day on the unmet need and innovations in hematopoietic stem cell transplant (HSCT).

Mr. Ross will be presenting at the Innovations in Solid Organ and Hematopoietic Stem Cell Transplant Virtual Event on September 28th, 2022 at 10:00 am CT. Registration for the event can be found here.

About Miromatrix Miromatrix Medical Inc. is a life sciences company pioneering a novel technology for bioengineering fully transplantable human organs to help save and improve patients' lives. The Company has developed a proprietary perfusion technology platform for bioengineering organs that it believes will efficiently scale to address the shortage of available human organs. The Company's initial development focus is on human livers and kidneys. For more information, visitmiromatrix.com.

Investor Contact Greg Chodaczek 347-620-7010 ir@miromatrix.com

Media Contact: press@miromatrix.com

Follow this link:
Miromatrix CEO Jeff Ross to Present at the Innovations in Solid Organ and Hematopoietic Stem Cell Transplant Virtual Event - GlobeNewswire

Deciphering the dynamics of the ovarian reserve in cynomolgus monkey through a quantitative morphometric study – EurekAlert

image:Graphical abstract of this study. A total of 18 ovaries from 16 cynomolgus monkeys were collected and separated into five developmental stages: perinatal period (E140, 8-day-old [8 d]), preadolescence (13 years), adolescence (45 years), adulthood (615 years), and perimenopause (1623 years). Immunofluorescent staining and H&E staining of ovaries were performed to investigate the dynamics of the cynomolgus monkey ovarian reserve and the establishment of the primordial follicle pool. Serum samples were collected to analyze the hormone levels. view more

Credit: Science China Press

This study is led by Prof. Hongmei Wang (State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences), Prof. Lan Zhu (Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College), Prof. Xiaokui Yang (Department of Human Reproductive Medicine, Beijing Obstetrics and Gynecology Hospital, Capital Medical University), and Dr. Long Yan (State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences).

Female reproduction and health are highly dependent on ovarian function. Ovarian reserve is a critical indicator of ovarian function. A systematic study of the ovarian reserve covering the human lifespan would benefit the understanding and treatment of reproductive aging under physiological and pathological conditions. However, due to ethical constraints and limited access to intact disease-free human ovarian tissues, research on the ovarian reserve in healthy women throughout their lifespan is limited. Non-human primates share similar genetic and physiological properties with humans and are considered an ideal model for studying the human ovarian reserve covering the lifespan. However, to date, there is no literature on the ovarian reserve covering the lifespan of non-human primates.

Wan Tu et al. used modern stereology techniques to count follicles and revealed the dynamics of the cynomolgus monkey (Macaca fascicularis) ovarian reserve covering its lifespan. The number of primordial follicles decreased with age: perinatal period (1.5 105 on average), preadolescence (1.2 105 on average), adolescence (7.7 104 on average), adulthood (4.3 104 on average) and perimenopause (2.5 103 on average). These results suggested that the ovarian reserve was abundant in the perinatal monkey ovary, then sharply declined during adolescent and adult ovaries, finally exhausted in the perimenopausal monkey ovary.

To investigate the establishment of primordial follicle pool, they performed immunofluorescent staining and H&E staining of perinatal monkey ovaries. The results suggested that the establishment of the primordial follicle pool in cynomolgus monkeys was initiated before E90 and was accomplished in two weeks after birth. Accompanied by the dynamics of ovarian reserve, ovarian fibrosis and oxidative DNA damage level were increased significantly with age. Moreover, they found that the age-related trend in AMH (anti-Mllerian hormone) levels in cynomolgus monkeys was consistent with that in humans, suggesting that AMH could also be a predictor of ovarian reserve in cynomolgus monkeys.

In summary, they depicted the dynamics of the ovarian reserve in cynomolgus monkeys covering their lifespan, provided evidence to show the establishment of the primate primordial follicle pool, and the correlation between the dynamics of ovarian reserve and ovarian microenvironmental changes. This study provided a solid foundation for investigating the mechanisms of ovarian aging and reproductive medicine research.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

Read this article:
Deciphering the dynamics of the ovarian reserve in cynomolgus monkey through a quantitative morphometric study - EurekAlert

Research Looks to Improve Outcomes in TP53-Mutant AML and MDS – Targeted Oncology

Melhem Solh, MD, discusses his research on post-transplant outcomes of patients with TP53-mutant acute myeloid leukemia and myelodysplastic syndrome.

Melhem Solh, MD, medical director for the Cellular Therapy Program at Northside Hospital, discusses his research on post-transplant outcomes of patients with TP53-mutant acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

Investigators, including Solh, examined 30 patients to evaluate overall survival (OS), relapse and non-relapse mortality, and disease-free survival (DFS) in patients with AML or MDS with a TP53 mutation and who had underwent an allogeneic hematopoietic stem cell transplant for this indication.

Due to the poor outcomes and survival rates seen for these patients, Sohl notes that the purpose of this trial is to further understand and improve options in this patient population.

Transcription:

0:08 | In this presentation, we looked at a group of patients who have AML [or] high-risk MDS who underwent an allogeneic transplant in our program for this indication. We looked at several end points, including OS, DFS, relapse and non-relapse mortality.

0:31 | The reason we're doing this is because patients who have TP53, which is a tumor suppressor gene on chromosome 17, tend to have very poor outcomes. If you look at patients with AML and MDS, their outcomes are usually very low and 1-year survival is very low. Even with transplant, historically, it's been reported to be less than 30%.

0:57 | Now, at this day and age, the improvement in attachment outcomes is newer medications that we can use to help get patients into deeper remission before transplant. That question [is], can we save some of these patients by taking them to an allogeneic transplant?

Read more:
Research Looks to Improve Outcomes in TP53-Mutant AML and MDS - Targeted Oncology

Stem Cell Assay Market Size And Forecast To 2022 |Thermo Fisher Scientific, Perkinelmer, Stemcell Technologies, Merck, Bio-Rad Laboratories The Colby…

Los Angeles, USA: A recent report published by Verified Market Research, titled [Global Stem Cell Assay Market, History and Forecasts for 2022-2029, data broken down by manufacturers, key regions, types and applications], contains an in-depth analysis of the Global Stem Cell Assay Market. The research report is divided in such a way as to highlight the key areas of the market and give the reader a complete picture. The report examines various aspects of the Stem Cell Assay market, such as its opportunities to explore its driving forces and limitations, market size, market segment analysis, regional prospects, key players and the competitive environment. Market Research Report Stem Cell Assay uses the methodology of primary and secondary research to provide accurate data to its readers. To fully assess the market and key players. Analysts also used SWOT analysis and analysis of Porters five strengths.

In the Global Stem Cell Assay Market, analysts provided historical and forecast data on the market, as well as the expected growth of average annual indicators. This will help the reader to evaluate the market in terms of its growth.

Stem Cell Assay Market size was valued at USD 927.60 Million in 2020 and is projected to reach USD 3714.13 Million by 2028, growing at a CAGR of 20.43% from 2021 to 2028.

Get a Sample Copy (Including FULL TOC, Graphs And Tables) Of This Report @ https://www.verifiedmarketresearch.com/download-sample?rid=24266

Global Stem Cell Assay Market : Drivers and Restraints

In this chapter, the report provides a full explanation of the driving forces of the market. It highlights the main driving forces of the market, which are expected to make a significant contribution to the growth of the market. It covers various industries that are developing in the same field, identifies the main areas of application and determines which of them will play an important role. The report also examines some of the new technologies and developments presented by manufacturers that are expected to become notable engines for the global Stem Cell Assay market.

This chapter also gives the reader important information regarding restrictions that may hinder the growth of the Stem Cell Assay market in the future. This research report discussed factors such as changes in land prices, labor and production costs, environmental issues, new government policies and business standards. In addition, the analysts also gave an idea of the potential opportunities existing in the global market of Stem Cell Assay. It offers a new perspective of turning threats into viable options to give the company a chance to win.

Global Stem Cell Assay Market : Competitive rivalry

The research report includes an analysis of the competitive environment present in the Global Stem Cell Assay Market. It includes an assessment of current and future trends in which players can invest. In addition, it also includes an assessment of the financial prospects of the players and explains the nature of the competition.

Key Players mentioned in the Global Market Research Report Stem Cell Assay Market:

Market segmentation of Stem Cell Assay market:

Stem Cell Assay market is divided by type and application. For the period 2021-2028, cross-segment growth provides accurate calculations and forecasts of sales by Type and Application in terms of volume and value. This analysis can help you grow your business by targeting qualified niche markets.

Stem Cell Assay Market by Product

Reagents and Kits Instruments

Stem Cell Assay Market by Application

Regenerative Medicine and Therapy Clinical Research Drug Discovery and Development

Stem Cell Assay Market by Assay

Cell Identification Assays Viability or Cytotoxicity Assays Apoptosis Assays Isolation & Purification Assays Others

Get Exclusive Discount on this Premium Report @ https://www.verifiedmarketresearch.com/ask-for-discount?rid=24266

Stem Cell Assay Market Report Scope

Global Stem Cell Assay Market: Regional segmentation

For further understanding, the research report includes a geographical segmentation of the Global Stem Cell Assay Market. It provides an assessment of the volatility of political scenarios and changes that may be made to regulatory structures. This estimate provides an accurate analysis of the regional growth of the Global Stem Cell Assay Market.

Middle East and Africa (GCC countries and Egypt) North America (USA, Mexico and Canada) South America (Brazil, etc.) Europe (Turkey, Germany, Russia, Great Britain, Italy, France, etc.) Asia-Pacific region (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia and Australia)

Global Stem Cell Assay Market: Research methodology

The research methodologies used by analysts play a crucial role in how the publication was compiled. Analysts used primary and secondary research methodologies to create a comprehensive analysis. For an accurate and accurate analysis of the Global Stem Cell Assay Market, analysts use ascending and descending approaches.

Table of Contents

Report Overview:It includes major players of the global Stem Cell Assay Market covered in the research study, research scope, and Market segments by type, market segments by application, years considered for the research study, and objectives of the report.

Global Growth Trends:This section focuses on industry trends where market drivers and top market trends are shed light upon. It also provides growth rates of key producers operating in the global Stem Cell Assay Market. Furthermore, it offers production and capacity analysis where marketing pricing trends, capacity, production, and production value of the global Stem Cell Assay Market are discussed.

Market Share by Manufacturers:Here, the report provides details about revenue by manufacturers, production and capacity by manufacturers, price by manufacturers, expansion plans, mergers and acquisitions, and products, market entry dates, distribution, and market areas of key manufacturers.

Market Size by Type:This section concentrates on product type segments where production value market share, price, and production market share by product type are discussed.

Market Size by Application:Besides an overview of the global Stem Cell Assay Market by application, it gives a study on the consumption in the global Stem Cell Assay Market by application.

Production by Region:Here, the production value growth rate, production growth rate, import and export, and key players of each regional market are provided.

Consumption by Region:This section provides information on the consumption in each regional market studied in the report. The consumption is discussed on the basis of country, application, and product type.

Company Profiles:Almost all leading players of the global Stem Cell Assay Market are profiled in this section. The analysts have provided information about their recent developments in the global Stem Cell Assay Market, products, revenue, production, business, and company.

Market Forecast by Production:The production and production value forecasts included in this section are for the global Stem Cell Assay Market as well as for key regional markets.

Market Forecast by Consumption:The consumption and consumption value forecasts included in this section are for the global Stem Cell Assay Market as well as for key regional markets.

Value Chain and Sales Analysis:It deeply analyzes customers, distributors, sales channels, and value chain of the global Stem Cell Assay Market.

To Gain More Insights into the Market Analysis, Browse Summary of the Research Report @https://www.verifiedmarketresearch.com/product/stem-cell-assay-market/

Visualize Anesthesia Delivery Systems Market using Verified Market Intelligence:-

Verified Market Intelligence is our BI-enabled platform for narrative storytelling of this market. VMI offers in-depth forecasted trends and accurate Insights on over 20,000+ emerging & niche markets, helping you make critical revenue-impacting decisions for a brilliant future.

VMI provides a holistic overview and global competitive landscape with respect to Region, Country, and Segment, and Key players of your market. Present your Market Report & findings with an inbuilt presentation feature saving over 70% of your time and resources for Investor, Sales & Marketing, R&D, and Product Development pitches. VMI enables data delivery In Excel and Interactive PDF formats with over 15+ Key Market Indicators for your market.

Visualize Anesthesia Delivery Systems Market using VMI @https://www.verifiedmarketresearch.com/vmintelligence/

About us

Verified Market Research is the Globals leading research and consulting firm serving more than 5,000 clients. Verified market research provides advanced analytical research solutions, offering research enriched with information. We offer information about strategic analysis and growth, data needed to achieve business goals, and important revenue decisions.

Our 250 analysts and representatives of small and medium-sized businesses have a high level of knowledge in the field of data collection and management. They use industrial methods to collect and analyze data in more than 15,000 highly efficient niches and markets. Our analysts are trained to combine modern data collection methods, excellent research methodologies, years of collective experience and expertise to conduct informative and accurate research.

We study more than 14 categories of semiconductors and electronics, chemicals, advanced materials, aerospace and defense industries, energy and consumables, healthcare, pharmaceuticals, Automotive and Transportation, Information and Communication Technologies, software and services, information security, mining, minerals and metals, construction, agricultural industry and medical equipment from in more than 100 countries.

Contact us

Dwayne Fernandez

Verified Market Research ABOUT US: +1 (650)-781-4080 United Kingdom: +44 (753)-715-0008 APAC: +61 (488)-85-9400 Free in the United States.: +1 (800)-782-1768

Originally posted here:
Stem Cell Assay Market Size And Forecast To 2022 |Thermo Fisher Scientific, Perkinelmer, Stemcell Technologies, Merck, Bio-Rad Laboratories The Colby...

Stem Cells Market 2022 Valuable Growth Prospects Analysis by 2028 | Osiris Therapeutics, NuVasive, Chiesi Pharmaceuticals, Medi-post The Colby Echo…

The MarketsandResearch.biz has scattered the new report, entitled Global Stem Cells Market from 2022 to 2028. The report is invigorated with market information, for instance, key industry plans, speculation openings, late new development, find, fundamental circumstance, and driving movement keeping watch. Furthermore, the Stem Cells market report wraps up on current assessment of mechanical advancement, progress, and new thing invigorates.

The focal techniques of the Stem Cells market report joins the key alliance profiles and their compensation rates close by their piece of the general business. Further, the affiliation profile region contains an association layout, thing portfolio, quantifiable data, and limitless activities. Moreover, the report brings into merge in fact the latest cases of the market. It merges market size, market evaluation, bargains volume, creation, and use data both in worth and volume.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketsandresearch.biz/sample-request/254845

The screens have completely condemned the irrefutable focal spaces of the if all else fails Stem Cells market. These areas have been outlined subject to clear data, present data, and measure data, close by the advancement rate. Similarly, the report other than gives an all around assessment of the Covid19 impact opens. The report further destroys heads five forces, regard chain, and stock affiliation appraisal. Nearby this, the concentrate other than wraps the geological evaluation subject to key area and countries.

The countries related with the report are

The central people covered in the report are

Thinking about the sort, the report is coordinated into

Considering the application, the information is aggregated into

ACCESS FULL REPORT: https://www.marketsandresearch.biz/report/254845/global-stem-cells-market-2022-by-company-regions-type-and-application-forecast-to-2028

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team (sales@marketsandresearch.biz), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on 1-201-465-4211 to share your research requirements.

Contact Us Mark Stone Head of Business Development Phone: 1-201-465-4211 Email: sales@marketsandresearch.biz

See the rest here:
Stem Cells Market 2022 Valuable Growth Prospects Analysis by 2028 | Osiris Therapeutics, NuVasive, Chiesi Pharmaceuticals, Medi-post The Colby Echo...

CAR-T Cell Therapy Completely Cures Autoimmune Disease in Several Patients – Inside Precision Medicine

Researchers at Friedrich-Alexander-University Erlangen-Nrnberg (FAU), in Germany have successfully cured several patients suffering from severe systemic lupus erythematosus (SLE) using genetically modified immune cells known as CAR-T cells.

CAR T cells are immune cells taken from an individual patient and genetically engineered to express proteins known as CARchimeric antigen receptorson their surface in order to bind specific proteins on the surface of target cells and eliminate them. CAR-T cells are a form of personalized therapy and already approved as a treatment for several cancers in the U.S.

In the first study of its kind, published in Nature Medicine, researchers at FAU have now modified CAR T cells to attack immune cells known as B cells which produce harmful antibodies against the bodys own cells in autoimmune diseases such as SLE, with astonishing results.

We have been able to help six young patients who were suffering from a life-threatening form of SLE and cure them of the disease completely by treating them with CAR-T cells, said Prof. Georg Schett, PhD, director of the Department of Medicine at FAU and senior author of the study in a press statement.

SLE is a severe form of autoimmune disease in which immune cells form antibodies that attack the bodys own DNA leading to the inflammation of internal organs. Patients suffering from the disease are often dependent on immunosuppressive drugs in order to manage the symptoms such as extreme fatigue and joint pain. For their trial, the researchers recruited treatment-resistant SLE patients with all trial participants showing damage in multiple organs, such as the kidneys, heart and lungs.

What is special about this is that a single infusion of CAR-T cells brought down the inflammation and autoimmune response like a house of cards, and the patients were able to stop all therapy including corticosteroids, said Schett.

The researchers compared the treatment to pressing a reset button in the immune system. According to Prof. Dimitros Mougiakakos, PhD, director of the department of hematology, oncology and stem cell transplantation at the University of Magdeburg and co-author of the study, 100 days after CAR T cell therapy the B cells returned but the disease continued to stay away.

When the immune system of treated patients is examined, it is surprising that the newly-emerged B cells are naive, similar to a baby. We can therefore be confident is saying that a reset button really has been pressed here, said Prof. Gerhard Krnke, PhD, professor of translational immunology at FAU and co-author of the study in a press statement.

However, due to not only diseased but all B-cells being eliminated, CAR T cell therapy carries a risk of causing cytokine release syndrome in which T cells produce pro-inflammatory molecules known as cytokines into the bloodstream, thus making the therapy potentially unsuitable for patients with only mild symptoms.

To ensure the CAR T cell therapy didnt harm the immune system of the patients in the trial, the researchers tested their antibody amounts in response to several vaccines such as measles, mumps and hepatitis B before and after the treatment. Overall, they didnt find a significant difference in antibody titers concluding that the CAR T cells mainly destroy the disease-causing B-cells producing autoantibodies.

As a next step the scientists at FAU are planning to conduct a larger basket clinical trial, where patients with different kinds of severe autoimmune diseases will receive CAR T cell therapy.

Continued here:
CAR-T Cell Therapy Completely Cures Autoimmune Disease in Several Patients - Inside Precision Medicine

Biopreservation Market worth USD 9.5 Billion by 2030, says Global Market Insights Inc. – GlobeNewswire

Selbyville, Delaware, Sept. 26, 2022 (GLOBE NEWSWIRE) --

The biopreservation market value is anticipated to cross USD 9.5 billion in revenue by 2030, according to a new research report by Global Market Insights Inc.

Increasing demand for regeneration medicines due to rising occurrences of lifestyle diseases will drive the industry trends. Growing need for effective healthcare systems, along with prominent healthcare expenditure, will increase the demand for biopreservatives. The soaring cases of chronic diseases among the elderly population have encouraged government agencies to spend massively on healthcare, pushing gene banks, bio banks and hospitals to focus on biopreservation.

Request for a sample of this research report @ https://www.gminsights.com/request-sample/detail/762

Wide applicability in research laboratories to push the industry landscape

Biopreservation market from equipment segment was valued at over USD 3.5 billion in 2021, due to the growing demand for biopreservation equipment to preserve blood, vaccines, and more, in hospitals and laboratories. The equipment includes freezers, refrigerators, consumables, and liquid nitrogen and are widely utilized in DNA, stem cell, plasma, and tissue research sectors.

CD34+ cell provider segment to foster market expansion

The CD34+ segment was worth more than USD 810 million in 2021. This is attributed to the prevalent use of cell surface marker CD34+ for the diagnosis of hematopoietic stem cells that can differentiate into multiple lineages. Blood from newborns umbilical cords is a crucial source of these cells. Notable advancements in stem cell research will stimulate product penetration.

Browse key industry insights spread across 260 pages with 413 market data tables & 13 figures & charts from the report, Biopreservation Market Analysis By Product (Equipment {Freezers, Refrigerators, Consumables [Vials, Straws, Microtiter, Bags], Liquid Nitrogen}, Media {Pre-formulated, Home-brew}, Laboratory Information Management System [LIMS]), By Application (Regenerative Medicine {Cell Therapy, Gene Therapy}, Biobanking {Human Eggs, Human Sperm, Veterinary IVF}, Drug Discovery), By Cell Provider (CD34+, CD19+, MSC, iPSC, hESC, Tumor Cells), Industry Analysis Report, Regional Outlook Growth Potential, Competitive Market Share & Forecast, 2022 2030 in detail along with the table of contents:

https://www.gminsights.com/industry-analysis/biopreservation-market

High demand for advanced storage facility to boost industry size

Biopreservation market from regenerative medicine segment accounted USD 1 billion in 2021. owing tothe rising demand for advancedbio storage facilities. Intensifying demand for regenerative therapies that require regenerative medicines will propel the demand for effective bio-storage procedures. For instance, in September 2022, CIRM provided around $2.7 million to UCI to establish a regenerative medicine training program to spread awareness regarding its benefits.

North America to emerge as a prominent regional market due to surging incidences of chronic diseases

North America biopreservation market held a substantial industry share of more than 45% in 2021 and is slated to depict significant growth over the assessment timeframe. Exponential demand for diagnosis of chronic diseases may be a key factor pushing regional market revenue. In addition, government guidelines supporting ethical usage of biological samples and the development of novel drugs & therapies in the healthcare space will foster the North America industry outlook.

Effective expansion plans to remain a vital development strategy for industry players

The competitive landscape of the biopreservation market is inclusive of Arctiko A/S, Thermo Fisher Scientific Inc, PHC Holdings Corporation, Cryport, Inc, Eppendorf AG, Helmer Scientific, VWR International (Avantor, Inc.), Biolife Solutions, Azenta, and Merck KGaA. These companies primarily focus on research and development and enter into strategic mergers and collaborations to proliferate their market position.

Request for customization of this research report @ https://www.gminsights.com/roc/762

About Global Market Insights

Global Market Insights Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider, offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with penetrative insights and actionable market data specially designed and presented to aid strategic decision making. These exhaustive reports are designed via a proprietary research methodology and are available for key industries such as chemicals, advanced materials, technology, renewable energy, and biotechnology.

Go here to see the original:
Biopreservation Market worth USD 9.5 Billion by 2030, says Global Market Insights Inc. - GlobeNewswire

A glimpse into Indian consumers expectations for cosmetic treatments and consumption insights – The Financial Express

By Dr Chytra V Anand

The fascination with beauty and skincare in India has grown leaps and bounds in recent times, and understandably so, given that the culture of beauty is deeply rooted in the country. The days when beauty was an aspect of social class and the cosmetic treatments and products you access gave away your economic status are long gone, as are the days when cosmetic treatments were considered a girl thing. With cosmetic treatments becoming more accessible and sought-after, the Indian skincare and derma cosmetics market generated an estimated revenue of a whopping USD 188.2 million in 2021. The same is projected to grow at a CAGR of 10.2% between 2021 and 2030.

Today, with changing lifestyles, demographic growth, cutting-edge technology, and improving economic and social conditions thanks to rising per capita and disposable income, India is quickly heading towards becoming a leader in the global cosmetics industry. But for a bit of self-introspection, what are Indian consumers looking for when it comes to cosmetic treatments? What does their consumption tell industry players?

Alzheimers is the most common form of dementia

Nutraceuticals: A healthy alternative to pharmaceutical drugs

We wish to leverage technology to make Yoga accessible to everybody globally: Karan Talreja, RESET Tech

Should you drink water before or after brushing your teeth? Read on to find out

Body hair removal has become one of the most popular cosmetic procedures done across the world today. But compared to shaving, waxing, or using an epilator or a trimmer, laser hair removal is a more permanent hair removal method that has gained immense traction of late. Especially in urban India, laser hair removal has quickly gained popularity, with mothers even bringing their 16-year-olds for Laser hair removal.

In 2021, the global laser hair removal market was valued atUSD 798.6 million, with an estimated CAGR of 18.4% from 2022 to 2030. Given that laser hair removal is a one-time procedure, although one has to sit through multiple sessions, the results, when done by a reliable cosmetic professional, are impressive. The Asia Pacific is projected to be the fastest-growing segment for laser hair removal, especially in countries like India and China.

A cosmetic procedure where a chemical solution is applied to your skin to remove the top layers, Chemical Peels ensure that the skin becomes smoother and clearer, making it radiant. On the other hand, a Medical Clean-up, in the simplest terms, is the procedure of cleaning your skin, ridding impurities like blackheads and white head spots to clear clogged pores. Besides, Medical Clean-ups are also beneficial for people struggling with acne scars, making it a popular procedure that an increasing number of people are choosing. For Chemical Peels, the market size is expected to touch USD 68.81 million between 2021 to 2025, making their popularity surge.

As we grow older, our skin begins to age too, and wrinkles and fine lines begin to appear on our face. Cosmetic procedures like Hydra Facials and skin maintenance with Laser Photofacials are a weekly must-do for 30-45-year-olds to ensure their skin is supple and glowing. Apart from this, the perception of Indian consumers when it comes to cosmetic treatments like Botox and Fillers has begun to change. These are no longer viewed as taboo as people now realise that they give your skin a lift.

Such treatments are also no longer only available for a certain section of society, like the wealthy. Botox and Fillers are now available to everyone, and consumers are looking at them from a skin maintenance standpoint rather than as a luxury, unnecessary treatment. Annually, the Botox segment is registering 20-25% growth in the country proof of evolving consumer preferences and the rising popularity of such treatments. Besides these, derma cosmetics and medical skin care have also gained a fair amount of traction, with skincare aficionados looking for effective and efficient skin care procedures that are non-surgical.

Alongside our skincare, taking care of our mane is equally important. For people struggling with hair fall, flaky and dry scalp, and other issues that affect your hair, stem cell therapy is the answer. Often done annually, stem cell therapy helps rejuvenate your hair cells to retain hair and repair damage. And with the global hair restoration market standing at over USD 4.2 billion in 2020, we can safely say its here to stay.

With consumerism changing face gradually and Indian consumers gaining access to world-class cosmetic treatments that are non-surgical, which still trump surgical procedures, the future of the Indian cosmetic treatments market shines bright. As long as the procedures are done by qualified and experienced professionals and are reliable and effective, the demand for such cosmetic procedures will continue to grow.

(The author isfounder ofKosmoderma Healthcare Pvt. Ltd.Views expressed are personal and do not reflect the official position or policy of the FinancialExpress.com.)

See the original post here:
A glimpse into Indian consumers expectations for cosmetic treatments and consumption insights - The Financial Express

20220927 Seven New CSL Global Research Acceleration Initiative Awardees Announced – CSL Limited

MELBOURNE, AUSTRALIA - 27 September 2022:Seven medical researchers have been awarded a CSL Research Acceleration Initiative (RAI) partnership, including up to an AU$500,000 investment in each program over two years, to fast-track the discovery of innovative biotherapies to address unmet medical needs.

The CSL Research Acceleration Initiative establishes partnerships between CSL and global research organisations to accelerate commercialisation of promising discovery programs. In addition to creating long-term mutual partnerships to further innovation, the initiative includes funding as well as access to CSL R&D experts.

The seven Global RAI awardees, selected via the 2021 call for proposals, include researchers from: The University of Queensland, University of Newcastle and ANZAC Research Institute in Australia; University of Pennsylvania in the US; Justus Liebig University Giessen and University Hospital of Ludwig Maximilian University of Munich in Germany; and University of Basel in Switzerland.

Dr Marthe DOmbrain, CSLs Head of Global Research Innovation said, Through our Global Research Acceleration Initiative, we are able to tap into and support research innovation happening in all corners of the world. We are looking forward to collaborating with our new partners to support the development of their exciting discoveries.

These Global RAI awardees research addresses important unmet medical needs across CSLs therapeutic areas, including immunology, transplant, respiratory, hematology, and cardiovascular and metabolic disease.

The investigators and technologies selected in the 2021 call for proposals include:

Professor Allison Pettit, The University of Queensland, Australia Prof. Pettit is exploring a new therapeutic approach to improve homing and engraftment of hematopoietic stem cell transplants. Prof Pettits program aims to reduce graft failure and risk of infection, thus significantly improving outcomes for patients.

Dr Kirsten Coupland, University of Newcastle, Australia Dr. Coupland is researching novel therapeutic targets for acute ischemic stroke, one of the leading causes of mortality worldwide. Dr Couplands work focuses on understanding how the composition of cerebrospinal fluid changes following a stroke.

Associate Professor Georgina Clark, ANZAC Research Institute, Australia A/Prof. Clark is developing a new treatment that could reduce the requirement for chemotherapy during a hematopoietic stem cell transplant, thus improving safety and enabling more patients to benefit from this potentially curative approach.

Professor Daniel Rader, University of Pennsylvania, United States of America Prof. Rader is developing a novel therapy for reducing triglycerides (a type of fat) in the blood. Patients with very high triglycerides can develop severe and sometimes life-threatening pancreatitis.

Professor Elie El Agha, Justus Liebig University Giessen, Germany Prof. El Agha's research program is focused on novel cellular and molecular pathways implicated in the pathobiology of idiopathic pulmonary fibrosis; a progressive lung disease that currently has no cure.

Professor Arthur Liesz, University Hospital of Ludwig Maximilian University of Munich, Germany Prof. Liesz investigates the interplay between our immune system and the brain. Understanding the role the immune system plays in exacerbating cardiovascular events, including in acute ischemic stroke and myocardial infarction, may identify novel treatment approaches.

Professor Daniel Ricklin, University of Basel, Switzerland Prof. Ricklin is developing novel therapeutic candidates to target inflammation. This approach could be applied to many serious diseases including immune complex mediated autoimmune disorders.

Dr DOmbrain said that the RAI recipients research addresses important unmet medical needs where there is often limited or no existing treatment options available for patients. We want to look back in years to come and see projects accelerated via our Research Acceleration Initiative making a difference to the lives of patients across the globe.

We look forward to helping transform these ideas into what we hope will ultimately be ground-breaking therapies to improve the lives of people living with these conditions, said Dr DOmbrain.

Providing life-saving medicines to patients in over 100 countries, CSL is driven by its promise to advance and deliver innovations that address rare and serious diseases as well as protect public health. Each year, CSLs Global Research Acceleration Initiative works to identify promising research programs around the world which will benefit most from fast-tracked industry collaboration and support. More than 25 new partnerships have been established via the Research Acceleration Initiative since 2019.

For more information about the CSL Research Acceleration Initiative, please visit: http://www.csl.com/csl-rai

Media ContactKim ODonohue M: +61 449 884 603 E: kim.odonohue@csl.com.au

About CSL CSL Limited (ASX:CSL; USOTC:CSLLY) is a leading global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, as well as vaccines to prevent influenza. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL including our three businesses, CSL Behring, CSL Seqirus and CSL Vifor provides lifesaving products to patients in more than 100 countries and employs 30,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. For inspiring stories about the promise of biotechnology, visit CSLBehring.com/Vita and follow us on Twitter.com/CSL. For more information visit csl.com.

Continued here:
20220927 Seven New CSL Global Research Acceleration Initiative Awardees Announced - CSL Limited

WHIM Syndrome: Market Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the market – Digital Journal

WHIM Syndrome Market I

DelveInsights WHIM Syndrome Market Insights, Epidemiology, and Market Forecast2032 report delivers an in-depth understanding of the WHIM Syndrome, historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

DelveInsights WHIM Syndrome Market Insights, Epidemiology, and Market Forecast2032 report delivers an in-depth understanding of the WHIM Syndrome, historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The WHIM Syndrome market report provides current treatment practices, emerging drugs, and their market share of the individual therapies, current and forecasted WHIM Syndrome symptoms market size from 2019 to 2032 segmented by seven major markets. The report also covers current WHIM Syndrome symptoms treatment practice/algorithm and unmet medical needs to curate the best opportunities. It assesses the underlying potential of the market.

Some of the key facts of the WHIM Syndrome Market Report:

Key benefits of the Whim Syndrome Market report:

With only symptomatic and no curative therapies approved in any markets, there exists a major unmet need for therapies that target the underlying cause of the disease to address the symptoms of WHIM Syndrome, to treat the patients effectively.

To counter unmet market needs and provide better treatment choices for WHIM Syndrome, several market players are working robustly either on single-agent novel molecules or on combination and dose modification of standard therapies. Several therapies are expected to be launched in the study period, likely to drive market growth during the study period.The major market players in WHIM Syndrome therapeutic market include X4 Pharmaceuticals, among others.

Got queries? Click here to know more about the Whim Syndrome Landscape

Whim Syndrome Market Overview

WHIM syndrome is a primary immunodeficiency disorder, one of a group of disorders characterized by irregularities in the cell development and/or cell maturation process of the immune system. The term WHIM is an acronym for the main signs of the syndrome: warts, hypogammaglobulinemia, infections, and myelokathexis. It is an autosomal-dominant combined immunodeficiency disease caused by mutations in the receptor CXCR4, resulting in increased bone marrow retention and severe reduction in circulating neutrophils.

WHIM Syndrome Diagnosis and Treatment

The treatment for WHIM syndrome can be mainly categorized into two categories: curative treatment and symptomatic treatment. Hematopoietic stem cell transplantation (allogenic) is the only available curative treatment for WHIM syndrome, whereas the symptomatic treatment involves the exogenous administration of immunoglobulins (IV/subcutaneous), G-CSF, and CXCR4 antagonists. Few major unmet needs in the market include no approved therapies, challenges in current symptomatic treatment options, challenges in hematopoietic stem cell transplantation (HSCT), lack of universal diagnostic criteria, and complicated diagnosis of the condition.

Whim Syndrome Market Epidemiological Insight

Whim Syndrome Market Epidemiological Segmentation

Whim Syndrome Market Outlook

The reports WHIM Syndrome market outlook helps to better understand the historic, current, and forecasted WHIM Syndrome market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of WHIM Syndrome market trend of each marketed drug and early-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to view the market at first sight.

According to DelveInsight, the WHIM Syndrome market in 7MM is expected to grow steadily during the study period 20192032.

The current management options for WHIM syndrome can be mainly categorized into two categories: curative treatment and symptomatic treatment. Hematopoietic stem cell transplantation (allogenic) is the only available curative treatment for WHIM syndrome, whereas the symptomatic treatment involves administration of granulocyte-colony stimulating factor (G-CSF), exogenous administration of immunoglobulins (IV/subcutaneous), G-CSF, and CXCR4 antagonists.

The major market players in WHIM Syndrome therapeutic market are Amgen, Sandoz (Novartis), Pfizer, Takeda, and X4 Pharmaceuticals, among others.

Learn more by requesting for sample @WHIM Syndrome Market Landscape

WHIM Syndrome Key Companies

WHIM Syndrome Therapies

Table of Contents

Click here to read more about WHIM Syndrome Market

Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Adya Kaul Email: Send Email Phone: 9193216187 Address:304 S. Jones Blvd #2432 City: Las Vegas State: Nevada Country: United States Website: https://www.delveinsight.com/

Originally posted here:
WHIM Syndrome: Market Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the market - Digital Journal